mntbap (Santa Cruz Biotechnology)
Structured Review

Mntbap, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mntbap/product/Santa Cruz Biotechnology
Average 93 stars, based on 18 article reviews
Images
1) Product Images from "MnTBAP, a peroxynitrite scavenger, attenuates cisplatin-induced apoptosis and cytotoxicity in organ of Corti cells"
Article Title: MnTBAP, a peroxynitrite scavenger, attenuates cisplatin-induced apoptosis and cytotoxicity in organ of Corti cells
Journal: Toxicology Reports
doi: 10.1016/j.toxrep.2025.101967
Figure Legend Snippet: Effect of MnTBAP cotreatment on the viability of cisplatin-treated UB/OC-1 cells. A) Dose-dependent cytotoxicity in UB/OC-1 cells after cisplatin treatment. B) Cell viability assay of UB/OC-1 cells after treatment with cisplatin, MnTBAP+Cisplatin, and MnTBAP alone indicates that the cisplatin-mediated cell death was attenuated with MnTBAP cotreatment Results are expressed as mean ± standard deviation, n = 7. ## p < 0.01 vs cisplatin.
Techniques Used: Viability Assay, Standard Deviation
Figure Legend Snippet: Effect of MnTBAP cotreatment on cisplatin-induced nitrative stress. A) Immunocytochemistry analysis with anti-nitrotyrosine was used to assess the nitrative stress in UB/OC-1 cells. Magenta staining indicates immunoreactivity to anti-nitrotyrosine while blue indicates nuclear staining with DAPI. B) Quantification of the immunostaining suggested that the level of 3-NT expression increased significantly with cisplatin treatment which was attenuated by MnTBAP cotreatment. The results are expressed as mean ± standard error, n = 6, ****p < 0.0001 vs control, #### p < 0.0001 vs cisplatin, scale bar = 20 µm.
Techniques Used: Immunocytochemistry, Staining, Immunostaining, Expressing, Control
Figure Legend Snippet: Effect of MnTBAP cotreatment on cisplatin-induced changes in the expression levels of apoptotic genes. A) Heat map depicts differentially expressed apoptotic genes in UB/OC-1 cells. The expression levels of genes in each treatment group were normalized with control. B) Cisplatin treatment induced the upregulation of many pro-apoptotic genes, while MnTBAP cotreatment attenuated their expression. MnTBAP cotreatment also upregulated the expression of anti-apoptotic genes. Results expressed as mean ± standard deviation, # p < 0.05, ## p < 0.01, n = 4.
Techniques Used: Expressing, Control, Standard Deviation
Figure Legend Snippet: Effect of MnTBAP cotreatment on cisplatin-induced changes in the expression levels of activated Caspase-3. A) Immunocytochemistry analysis of UB/OC-1 cell lines with anti-caspase-3 was used to assess apoptosis. Orange staining indicates immunoreactivity to anti-Caspase-3 while blue indicates nuclear staining with DAPI. B) Quantification of the staining intensity suggested that the level of activated Caspase-3 expression increased significantly with cisplatin treatment which was attenuated by MnTBAP cotreatment. The results are expressed as mean ± standard error, n = 6, ****p < 0.0001 vs control, #### p < 0.0001 vs cisplatin, scale bar = 20 µm.
Techniques Used: Expressing, Immunocytochemistry, Staining, Control
Figure Legend Snippet: Effect of MnTBAP cotreatment on cisplatin-induced decrease in LMO4 levels. A) Immunoblot analysis with anti-LMO4 was used to assess LMO4 protein levels in UB/OC-1 cells. Actin was used for normalization. B) Quantification of the bands indicated that cisplatin treatment reduced LMO4 protein levels, while cotreatment with MnTBAP attenuated the cisplatin-mediated decrease in LMO4 levels. The results are expressed as mean ± standard error, n = 4, **p < 0.01 vs control, #### p < 0.01 vs cisplatin.
Techniques Used: Western Blot, Control
